Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [41] Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis
    Zhang, Jianchao
    Tang, Junnan
    Cui, Xiaolin
    Wang, Bo
    Bu, Mengsen
    Bai, Yan
    Wang, Kai
    Guo, Jiacheng
    Shen, Deliang
    Zhang, Jinying
    BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
  • [42] Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
    Generalova, Daria
    Cunningham, Scott
    Leslie, Stephen J.
    Rushworth, Gordon F.
    Mciver, Laura
    Stewart, Derek
    PHARMACY PRACTICE-GRANADA, 2020, 18 (02): : 1 - 6
  • [43] Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
    Welander, Frida
    Renlund, Henrik
    Dimeny, Emoeke
    Holmberg, Henrik
    Sjalander, Anders
    CLINICAL KIDNEY JOURNAL, 2023, 16 (05) : 835 - 844
  • [44] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Dhamane, Amol D.
    Ferri, Mauricio
    Keshishian, Allison
    Russ, Cristina
    Atreja, Nipun
    Gutierrez, Cynthia
    Emir, Birol
    Yuce, Huseyin
    Di Fusco, Manuela
    ADVANCES IN THERAPY, 2023, 40 (03) : 887 - 902
  • [45] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Amol D. Dhamane
    Mauricio Ferri
    Allison Keshishian
    Cristina Russ
    Nipun Atreja
    Cynthia Gutierrez
    Birol Emir
    Huseyin Yuce
    Manuela Di Fusco
    Advances in Therapy, 2023, 40 : 887 - 902
  • [46] Novel Anticoagulants in Prevention of Cardioembolic Stroke in Patiens with Non-Valvular Atrial Fibrillation
    Bauer, Jiri
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2013, 76 (05) : 550 - 558
  • [47] Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation
    Hohmann, Christopher
    Hohnloser, Stefan H.
    Jacob, Josephine
    Walker, Ochen
    Baldus, Stephan
    Pfister, Roman
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (06) : 971 - 980
  • [48] Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
    Kocis P.T.
    Liu G.
    Makenbaeva D.
    Trocio J.
    Velott D.
    Trainer J.A.B.
    Abdulsattar Y.
    Molina M.I.
    Leslie D.L.
    Drugs - Real World Outcomes, 2016, 3 (2) : 165 - 173
  • [49] Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
    Deitelzweig, Steven
    Keshishian, Allison
    Kang, Amiee
    Dhamane, Amol D.
    Luo, Xuemei
    Balachander, Neeraja
    Rosenblatt, Lisa
    Mardekian, Jack
    Jiang, Jenny
    Yuce, Huseyin
    Lip, Gregory Y. H.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [50] A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation
    Lopes, Renato D.
    Berger, Samantha E.
    Di Fusco, Manuela
    Kang, Amiee
    Russ, Cristina
    Afriyie, Abena
    Earley, Amy
    Deshpande, Sohan
    Mantovani, Lorenzo G.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 319 : 85 - 93